News & Events

• May 17, 2013
  

  Qualitative Assessment of Symptom Experience in Patients with Irritable Bowel Syndrome for the Development of Patient-Reported Outcome Instruments

• May 13, 2013
  

  Alignment of New Tuberculosis Drug Regimens and Drug Susceptibility Testing: A Framework for Action

  Wells WA, Boehme CC, Cobelens FGJ, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M. Alignment of New Tuberculosis Drug Regimens and Drug Susceptibility Testing: A Framework for Action. The Lancet Infectious Diseases. 2013 May;13(5):449–58.

• May 7, 2013
  

  Collaborating for Cures Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development CAMD Presentation

• May 1, 2013
  

  Tuberculosis Comorbidity with Communicable and Non-Communicable Diseases: Integrating Health Services and Control Efforts

  Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, Bates M, Colagiuri R, Zijenah L, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Abubakar I, Hasan R, Zafar A, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M, Zumla A. Tuberculosis Comorbidity with Communicable and Non-Communicable Diseases: Integrating Health Services and Control Efforts. The Lancet Infectious Diseases. 2013 May;13(5):436–48.

• April 24, 2013 - April 25, 2013
  

  Fourth Annual Patient-Reported Outcome (PRO) Consortium Workshop

  April 24 – 25, 2013 Sheraton Silver Spring Hotel 8777 Georgia Avenue – Silver Spring, MD 20910 SPONSORED BY: Critical Path Institute Food and Drug Administration (FDA) The Patient-Reported Outcome (PRO) Consortium is a public-private partnership established by the Critical Path Institute (C-Path) in cooperation with the U.S. Food and Drug Administration (FDA) and the...